↓ Skip to main content

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Overview of attention for article published in Maxillofacial Plastic and Reconstructive Surgery, December 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
15 Mendeley
Title
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Published in
Maxillofacial Plastic and Reconstructive Surgery, December 2017
DOI 10.1186/s40902-017-0136-y
Pubmed ID
Authors

Gian Paolo Bombeccari, Umberto Garagiola, Francesco Pallotti, Margherita Rossi, Massimo Porrini, Aldo Bruno Giannì, Francesco Spadari

Abstract

Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr-Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption, lichenoid reactions, erythroderma, and skin rash. Depigmentation of the skin and/or mucosa is uncommon, and hyperpigmentation is rare. We present the case of a 63-year-old Caucasian male with widespread hyperpigmentation of the hard palate associated with a 9-year history of imatinib therapy to treat CML. He did not complain of any symptoms. Clinical examination did not reveal any abnormal pigmentation of the skin or other region of the oral mucosa. He did not smoke cigarettes or drink alcohol. His medication regimen was a proton pump inhibitor, a beta-blocker, cardioaspirin, atorvastatin, and imatinib 400 mg/day. Histopathologically, melanin and haemosiderin deposits were evident in the lamina propria. The lesion persisted, with no clinical change, through several follow-ups. We reviewed the literature to explore the possible relationship between oral hyperpigmentation and long-term imatinib mesylate treatment. We diagnosed oral pigmentation associated with imatinib intake based on the medical history and clinical features of the pigmented macules. Oral pigmentation may have a variety of causes, and differential diagnosis requires nodal analysis. Clinicians should be aware of possible oral mucosal hyperpigmentation in patients taking imatinib mesylate. Such pigmentation is benign and no treatment is needed, but surveillance is advisable.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 20%
Student > Doctoral Student 2 13%
Student > Master 2 13%
Student > Bachelor 2 13%
Librarian 1 7%
Other 2 13%
Unknown 3 20%
Readers by discipline Count As %
Medicine and Dentistry 8 53%
Pharmacology, Toxicology and Pharmaceutical Science 2 13%
Social Sciences 1 7%
Unknown 4 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 January 2018.
All research outputs
#6,782,951
of 20,886,305 outputs
Outputs from Maxillofacial Plastic and Reconstructive Surgery
#6
of 59 outputs
Outputs of similar age
#158,513
of 440,611 outputs
Outputs of similar age from Maxillofacial Plastic and Reconstructive Surgery
#1
of 10 outputs
Altmetric has tracked 20,886,305 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 59 research outputs from this source. They receive a mean Attention Score of 1.5. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,611 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them